Evidence verdict: Cell-based treatments for knee osteoarthritis require product-specific evaluation. A report of less pain does not establish cartilage regrowth, and results from one procedure cannot automatically support a different clinic product.
If knee pain limits your life, avoiding surgery can be an understandable goal. The decision should begin with a clear diagnosis and a fair comparison of available options, including their likely benefits, risks, costs and uncertainties.
Ask which outcome improved
Pain scores, walking ability and cartilage structure answer different questions. Improvement in one does not prove improvement in another. A claim that treatment rebuilds cartilage needs appropriate structural evidence, not simply a patient saying the knee feels better.
A major trial deserves attention
The 2023 MILES randomized trial compared bone marrow aspirate concentrate, adipose stromal vascular fraction and umbilical cord tissue-derived MSCs with corticosteroid injections. None of the cell-based groups was superior to corticosteroid for the primary pain outcomes at one year. MRI osteoarthritis scores did not show significant improvement. Mautner et al., 2023.
That result should temper broad marketing promises. It does not prove that every cell product, dose or surgical tissue-engineering approach is ineffective. It tells us what those tested interventions achieved against that comparator.
Why the procedure matters
A 2026 review describes both encouraging and negative clinical findings. It also distinguishes injected products from surgical implantation of cord-blood-derived MSCs with a hydrogel. These are materially different interventions. Surgical cartilage-repair findings should not be presented as proof that a routine Wharton’s jelly injection or IV infusion rebuilds an arthritic knee. Next-generation therapies for osteoarthritis, 2026.
Questions worth taking to your consultation
- Is the proposed product the same as the one used in the cited trial?
- Was the treatment injected into the joint, infused intravenously, or surgically implanted?
- Did the trial measure pain, function, cartilage, or avoidance of surgery?
- How large was the benefit compared with the control group?
- How were nonresponse, complications and missing follow-up reported?
- What are my reasonable alternatives, and what is the downside of delaying them?
A responsible recommendation should not depend on portraying established care as merely masking symptoms. Your decision should reflect your diagnosis, preferences and the best applicable evidence.
Cell therapy remains an important research field. Its credibility grows when claims stay within the limits of the actual product and study.
Disclosure: Dr. Ramon De La Puerta is affiliated with Z-Lounge Regenerative Medicine and has a commercial interest in regenerative-medicine services. This relationship should be considered when reading this article. The discussion is educational and does not determine whether a treatment is appropriate for an individual patient.
Correction — September 11, 2026: This revision replaces general cartilage-regrowth and surgery-avoidance claims with a distinction between symptom and structural outcomes. Unverified numerical success claims and patient stories are omitted pending documentation.
